Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Ignacio Durán(Instituto de Biomedicina de Sevilla), Oriol Casanovas(Institut Català d'Oncologia), Pablo Maroto(Hospital de Sant Pau), Luis Esteves Flores(Novartis (Spain)), Sergio Granados‐Principal(Universidad de Granada), J. Lambea(Hospital Clínico Universitario Lozano Blesa), Ana Vivancos(Vall d'Hebron Institute of Oncology), Mariona Graupera(Josep Carreras Leukaemia Research Institute), Berta Sáez(Instituto de Nanociencia y Materiales de Aragón), J.L. González-Larriba(Hospital Clínico San Carlos)
Cited by 103
Related Papers
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k